RxDoctor Payments Data

Carl Allen Bernas, MD

Infectious Disease · Colorado Springs, CONPI 1841454311

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.7% of the total across 147 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Viiv Healthcare Company at 33.1% of the total. Reporting peaked in 2022 at $776 and has fallen 78.3% since, to $169 in 2025.

$2,793in general payments, 2019–2025

Across 147 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$925
  • Gilead$744
  • AbbVie$330
  • Merck$236
  • Insmed, Inc.$81
  • Astellas Pharma US Inc$79
  • plus $398 from 12 others

What the payments were for

  • Food & beverage$2,75799%
  • Education$361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,793 in reported general payments places this provider in the 85th percentile of 146 infectious disease providers in Colorado.

See all infectious disease providers in Colorado

Medicare billing

Part B allowed, 2024
$141,076
Medicare patients
314
Services billed
111,505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala50$206,856
GenvoyaElviteg/Cob/Emtri/Tenof Alafen13$78,732
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf13$61,359
TriumeqAbacavir/Dolutegravir/Lamivudi12$44,248
DovatoDolutegravir Sodium/Lamivudine14$41,300
DescovyEmtricitabine/Tenofov Alafenam12$25,899
Etravirine11$12,662
Daptomycin28$7,230
ErtapenemErtapenem Sodium15$4,152
Doxycycline Monohydrate35$2,233
Cefadroxil99$2,062
CeftriaxoneCeftriaxone Sodium33$1,835
Darunavir12$1,188
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav32$884
Rifampin12$759

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$744$311,48775 claims
Viiv Healthcare CompanyTriumeq, Dovato$925$85,54826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 146 infectious disease providers in Colorado.

Other infectious disease in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →